According to a new survey by the Kaiser Family Foundation, 62% of adults in the US fear President Donald Trump’s policies will result in a hasty vaccine.
In KFF’s telephone poll conducted between late August and early September, 62% of adults responded that they are “concerned that political pressure from the Trump administration will cause the FDA to approve a coronavirus vaccine without ensure that it is safe and effective. ” . “
Like polarized views on national issues relating to racial discrimination and immigration, Democrats and Republicans have been divided on the matter. 85% of Democrats and only 35% expressed concern about a rushed vaccine, according to the new poll.
Trump has signaled that a new vaccine could be ready in early November, a few days before the presidential election. In August, Trump claimed that a vaccine could be ready “around”
At a press conference Monday at the White House, Trump criticized Senator Kamala Harris for saying she would not trust the president with a coronavirus vaccine as “reckless rhetoric against vaccines” and again suggested that a vaccine could come as early as October. Earlier this month, CDC Director Robert Redfield asked the state governors to prepare to distribute vaccines by November 1.
However, public health experts have repeatedly stressed that Trump’s schedule is unrealistic, suggesting instead that a vaccine is expected to arrive by the end of this year or 2021. Earlier this month, CDC Director Robert Redfield asked the state governors to prepare for Dr. Anthony Fauci said Tuesday it was “unlikely” that a vaccine would be ready by the November elections, and stated that a vaccine is expected to be confirmed towards the end of the year.
Still, around 40% of adults said the FDA and CDC “pay too much attention” to politics, according to the KFF survey.
That sentiment comes amid reports that Trump administration officials have tried to water down reports from the CDC, Politico reported Friday night. A political officer accused professional researchers of attempting to undermine the president’s campaign to reopen schools.
To ensure public trust, the CEOs of leading pharmaceutical companies have jointly committed to validating the safety and effectiveness of vaccines through phase 3 clinical trials before seeking regulatory approval.